Credit Suisse Starts BioMarin Pharmaceutical Inc. (BMRN) at Outperform, $110 PT

Credit Suisse initiates coverage on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with a Outperform rating and a price target of $110.00.

Analyst Alethia Young commented, "We are initiating coverage of BioMarin with an Outperform rating and $110 TP. We have excluded DMD and hemophilia fully from our valuation and see upside from current levels. This is due to the pipeline, and we are positively inclined on many of the readouts in 16. Ex-US DMD approval and hemophilia would be big upside drivers in our valuation."

For an analyst ratings summary and ratings history on BioMarin Pharmaceutical Inc. click here. For more ratings news on BioMarin Pharmaceutical Inc. click here.

Shares of BioMarin Pharmaceutical Inc. closed at $79.51 yesterday.

You May Also Be Interested In

• BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $85 at Scotiabank
• BioMarin Pharma (BMRN) Tops Q1 EPS by 39c ; Offers Guidance
• Sage Therapeutics (SAGE) PT Lowered to $18 at Truist Securities